Your browser doesn't support javascript.
loading
Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.
Malarikova, Diana; Berkova, Adela; Obr, Ales; Blahovcova, Petra; Svaton, Michael; Forsterova, Kristina; Kriegova, Eva; Prihodova, Eva; Pavlistova, Lenka; Petrackova, Anna; Zemanova, Zuzana; Trneny, Marek; Klener, Pavel.
Afiliação
  • Malarikova D; First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic.
  • Berkova A; Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
  • Obr A; First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic.
  • Blahovcova P; Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
  • Svaton M; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic.
  • Forsterova K; First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic.
  • Kriegova E; CLIP, Department of Pediatric Hematology/Oncology, Second Faculty of Medicine and University Hospital in Motol, 15006 Prague, Czech Republic.
  • Prihodova E; First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic.
  • Pavlistova L; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic.
  • Petrackova A; Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
  • Zemanova Z; Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
  • Trneny M; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic.
  • Klener P; Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
Cancers (Basel) ; 12(8)2020 Jul 31.
Article em En | MEDLINE | ID: mdl-32751805
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: República Tcheca País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: República Tcheca País de publicação: Suíça